Bulletin
Investor Alert

April 25, 2018, 2:03 p.m. EDT

What to expect from marijuana stocks after the first big medical cannabis win

Companies including GW Pharmaceuticals could be takeover targets

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Nigam Arora

1 2

Buyout target

In our analysis at The Arora Report, GW Pharmaceuticals is a buyout target. To date, 134 of The Arora Report portfolio companies have been bought out. Buyouts produce great profits for investors, as suitors offer premiums to their share prices to get stockholders’ approval.

A buyout of GW Pharmaceuticals could potentially take place north of $200 a share. It recently traded at around $140. As a note of caution, there are no guarantees, of course.

Risks

The Arora Report classifies GW Pharmaceuticals as a speculative stock. We provide complete guidelines for investing in speculative stocks in our Trade Management Guidelines. The company faces many risks. Here are a few of them:

• There are many other competitors working on cannabis-based drugs. An example is Zynerba Pharmaceuticals /zigman2/quotes/204500323/composite ZYNE -1.55% .

• Many competitors are also working on epilepsy treatments. An example is Zogenix /zigman2/quotes/204255718/composite ZGNX -1.46% .

• Even though the rest of the pipeline of GW Pharmaceuticals seems promising, there is no guarantee that other drugs will become commercially successful.

• Biotech stocks tend to be very volatile. An adverse development in a trial can precipitate a large fall in the stock price.

• Biotech stocks, as a sector, often go through corrective phases.

What to do now

Under the circumstances, investors either ought to wait for a breakout from the resistance zone shown on the chart or a pullback to the support zone before buying.

The other reason to buy — if the two conditions above are not met — is if the smart money (professional investors) starts buying. Right now our algorithms at The Arora Report do not detect any smart-money buying.

Fortunes may be made

Irrespective of your own personal opinion of cannabis, all investors need to consider that fortunes may be made in cannabis over the coming years. On the medicinal side, there are a large number of molecules in cannabis with lots of promise. At The Arora Report we are on the hunt for the right opportunities to invest.

Primarily on the recreational side, cannabis stocks right now are very expensive. We are patiently waiting for six screens of the ZYX Change Method to give a buy signal. To learn more about the six screens, please click here . Investors may want to keep on their radar stocks of some of the larger publicly traded companies, including Cronos Group /zigman2/quotes/206842762/composite CRON -5.00% , Aurora Cannabis , Canopy Growth , Aphria and MedReleaf . For those interested in ETFs, keep on your radar ETFMG Alternative Harvest /zigman2/quotes/204332491/composite MJ -2.85% .

Click to Play

What every cannabis investor should be paranoid about

Disclosure: Subscribers to The Arora Report may have positions in the securities mentioned in this article. Nigam Arora is an investor, engineer and nuclear physicist by background who has founded two Inc. 500 fastest-growing companies. He is the founder of The Arora Report, which publishes four newsletters. Nigam can be reached at Nigam@TheAroraReport.com.

/zigman2/quotes/204500323/composite
US : U.S.: Nasdaq
$ 4.46
-0.07 -1.55%
Volume: 1.00M
Sept. 24, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$183.98 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/204255718/composite
US : U.S.: Nasdaq
$ 15.49
-0.23 -1.46%
Volume: 357,656
Sept. 24, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$865.86 million
Rev. per Employee
$62,583
loading...
/zigman2/quotes/206842762/composite
US : U.S.: Nasdaq
$ 5.70
-0.30 -5.00%
Volume: 2.23M
Sept. 24, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.11 billion
Rev. per Employee
$70,043
loading...
/zigman2/quotes/204332491/composite
US : U.S.: NYSE Arca
$ 14.67
-0.43 -2.85%
Volume: 728,938
Sept. 24, 2021 4:00p
loading...

Nigam Arora is an engineer, nuclear physicist, author, and entrepreneur and the founder of two Inc. 500 fastest growing companies. He is also the developer of the ZYX Change Method to profit from change by investing. The premise is that most money is made by predicting change before the crowd. Arora is the chief investment officer at The Arora Report and the editor of four newsletters that track the ZYX Change Method. Nigam can be reached at Nigam@TheAroraReport.com

1 2
This Story has 0 Comments
Be the first to comment
More News In
Investing

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.